CEBPZ and acute myeloid leukemia: Although the low number of patients enrolled hampers the analysis, this study suggested that CBF-AML patients with low levels of RT-PCR (0.01–0.05) at the end of induction/consolidation chemotherapy might have some benefit from maintenance HMA, particularly those that have a reduction in the RT-PCR within the first two cycles of HMA therapy.